A Phase I, Single-blind, Randomised, Placebo-controlled, Dose Escalation Study to Evaluate the Reactogenicity, Safety and Immune Response of an HSV Vaccine in Healthy Participants Aged 18-40 Years
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Percentage of participants reporting solicited administration site events within 7 days after the second vaccine dose administered at Day 57
研究概览
简要总结
The purpose of this first-time-in-human (FTiH) study is to assess the reactogenicity, safety and immunogenicity of four different dose levels of an experimental herpes simplex virus type 2 (HSV-2) vaccine, when administered intramuscularly (IM) on a 0, 2-month schedule to healthy participants aged 18-40 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants, who, in the opinion of the investigator, can and will comply with the requirements of the Protocol.
- •Written informed consent obtained from the participant prior to performance of any study-specific procedure.
- •Healthy participants as established by medical history and clinical examination before entering into the study.
- •Man or woman aged 18-40 years, included, at the time of the first vaccination.
- •Women of non-childbearing potential may be enrolled in the study.
- •Women of childbearing potential may be enrolled in the study, if the participant:
- •Has practiced adequate contraception for one month prior to vaccination, and;
- •Has a negative pregnancy test result on the day of vaccination, and;
- •Has agreed to continue adequate contraception until the end of the study.
- •Seronegative for HIV, as determined by laboratory screening tests. Participants documented to be positive to HIV will not be eligible for study participation.
- •Seronegative for HSV-2 as determined by Western blot.
排除标准
- •Medical Conditions
- •Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccines.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •Hypersensitivity to latex.
- •Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, endocrine, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- •Recurrent history or uncontrolled neurological disorders or seizures.
- •Grade 2 or higher haematological and/or biochemical laboratory abnormality at screening.
- •Body mass index ≤ 18 kg/m^2 or ≥ 35 kg/m^
- •History of any form of ocular HSV infection, HSV-related erythema multiforme, or HSV-related neurological complications.
- •Participants with symptoms suggestive of Coronavirus disease 2019 (COVID-19) infection within 14 days before the first study vaccination. Participants should be free of symptoms for at least 14 days.
- •Participants with known COVID-19-positive contacts in the past 14 days before the first study vaccination.
- •Prior/Concomitant Therapy
- •Use of any investigational or non-registered product other than the study vaccines during the period beginning 30 days before the first dose of study vaccine (Day -29 to Day 1), or planned use during the study period.
- •Planned administration/administration of a vaccine not foreseen by the Protocol in the period starting 15 days before each dose and ending 15 days after each dose of study vaccine administration.
- •Administration of long-acting immune-modifying drugs at any time during the study period.
- •Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting three months before the first dose of study vaccine or planned administration during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs during the period starting three months prior to the first study vaccine dose. For corticosteroids, this will mean prednisone equivalent ≥ 20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
- •Prior receipt of another vaccine containing HSV-2 antigens. Prior/Concurrent Clinical Study Experience
- •Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.
- •Other Exclusions
- •Pregnant or lactating woman.
- •Woman planning to become pregnant or planning to discontinue contraceptive precautions.
研究组 & 干预措施
HSV lower dose formulation Group
Healthy participants, 18 to 40 years of age, receive two doses of the HSV lower dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
干预措施: Lower dose formulation of HSV vaccine (GSK4108771A) (Biological)
Placebo Step 1 Group
Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
干预措施: Placebo (saline) (Drug)
HSV low dose formulation Group
Healthy participants, 18 to 40 years of age, receive two doses of the HSV low dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
干预措施: Low dose formulation of HSV vaccine (GSK4108771A) (Biological)
Placebo Step 2 Group
Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
干预措施: Placebo (saline) (Drug)
HSV medium dose formulation Group
Healthy participants, 18 to 40 years of age, receive two doses of the HSV medium dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
干预措施: Medium dose formulation of HSV vaccine (GSK4108771A) (Biological)
Placebo Step 3 Group
Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
干预措施: Placebo (saline) (Drug)
HSV high dose formulation Group
Healthy participants, 18 to 40 years of age, receive two doses of the HSV high dose formulation vaccine intramuscularly, one at Day 1 and one at Day 57.
干预措施: High dose formulation of HSV vaccine (GSK4108771A) (Biological)
Placebo Step 4 Group
Healthy participants, 18 to 40 years of age, receive two doses of placebo (saline) intramuscularly, one at Day 1 and one at Day 57.
干预措施: Placebo (saline) (Drug)
结局指标
主要结局
Percentage of participants reporting solicited administration site events within 7 days after the second vaccine dose administered at Day 57
时间窗: Within 7 days after the second vaccine dose (administered at Day 57)
The solicited administration site events are pain, redness and swelling.
Percentage of participants reporting solicited systemic events within 7 days after the second vaccine dose administered at Day 57
时间窗: Within 7 days after the second vaccine dose (administered at Day 57)
The solicited systemic events are fever, fatigue, headache, nausea, vomiting, diarrhoea, abdominal pain, myalgia and arthralgia. The preferred location for measuring temperature is the oral cavity. Fever is defined as temperature equal to or above (≥) 38.0 degree Celsius (°C)/ 100.4°F, regardless the location of measurement.
Percentage of participants reporting unsolicited adverse events (AEs) within 28 days after the first vaccine dose administered at Day 1
时间窗: Within 28 days after the first vaccine dose (administered at Day 1)
An unsolicited AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention, whether or not considered related to the study intervention and that was not included in a list of solicited events using a Participant Diary.
Percentage of participants reporting unsolicited adverse events (AEs) within 28 days after the second vaccine dose administered at Day 57
时间窗: Within 28 days after the second vaccine dose (administered at Day 57)
An unsolicited AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention, whether or not considered related to the study intervention and that was not included in a list of solicited events using a Participant Diary.
Percentage of participants reporting medically attended AEs (MAEs)
时间窗: From Day 1 up to study end at Day 421
A MAE is an unsolicited AE for which the participants received medical attention defined as hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.
Percentage of participants reporting potential orolabial HSV-1 recurrence
时间窗: From Day 1 up to study end at Day 421
Potential orolabial HSV-1 recurrence represents a subset of adverse events of special interest (AESIs).
Percentage of participants reporting serious adverse events (SAEs)
时间窗: From Day 1 up to study end at Day 421
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study patient or results in abnormal pregnancy outcomes.
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 58
时间窗: At Day 58
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. In the absence of a diagnosis, abnormal laboratory findings assessments (e.g., Grade 2 or higher abnormal haematological and biochemical parameters) or other abnormal results the investigator considers clinically significant are recorded as an AE or SAE, if they meet the definition of an AE or SAE.
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 64
时间窗: At Day 64
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. In the absence of a diagnosis, abnormal laboratory findings assessments (e.g., Grade 2 or higher abnormal haematological and biochemical parameters) or other abnormal results the investigator considers clinically significant are recorded as an AE or SAE, if they meet the definition of an AE or SAE.
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 85
时间窗: At Day 85
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. In the absence of a diagnosis, abnormal laboratory findings assessments (e.g., Grade 2 or higher abnormal haematological and biochemical parameters) or other abnormal results the investigator considers clinically significant are recorded as an AE or SAE, if they meet the definition of an AE or SAE.
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 2
时间窗: At Day 2
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. In the absence of a diagnosis, abnormal laboratory findings assessments (e.g., Grade 2 or higher abnormal haematological and biochemical parameters) or other abnormal results the investigator considers clinically significant are recorded as an AE or SAE, if they meet the definition of an AE or SAE.
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 8
时间窗: At Day 8
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. In the absence of a diagnosis, abnormal laboratory findings assessments (e.g., Grade 2 or higher abnormal haematological and biochemical parameters) or other abnormal results the investigator considers clinically significant are recorded as an AE or SAE, if they meet the definition of an AE or SAE.
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at Day 57
时间窗: At Day 57
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. In the absence of a diagnosis, abnormal laboratory findings assessments (e.g., Grade 2 or higher abnormal haematological and biochemical parameters) or other abnormal results the investigator considers clinically significant are recorded as an AE or SAE, if they meet the definition of an AE or SAE.
Percentage of participants reporting solicited administration site events within 7 days after the first vaccine dose administered at Day 1
时间窗: Within 7 days after the first vaccine dose (administered at Day 1)
The solicited administration site events are pain, redness and swelling.
Percentage of participants reporting solicited systemic events within 7 days after the first vaccine dose administered at Day 1
时间窗: Within 7 days after the first vaccine dose (administered at Day 1)
The solicited systemic events are fever, fatigue, headache, nausea, vomiting, diarrhoea, abdominal pain, myalgia and arthralgia. The preferred location for measuring temperature is the oral cavity. Fever is defined as temperature equal to or above (≥) 38.0 degree Celsius (°C)/ 100.4°F, regardless the location of measurement.
Percentage of participants reporting potential immune-mediated diseases (pIMDs)
时间窗: From Day 1 up to study end at Day 421
PIMDs are a subset of adverse events of special interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Percentage of participants reporting any haematological and biochemical laboratory abnormalities at pre-vaccination (Day 1)
时间窗: At pre-vaccination (Day 1)
Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. In the absence of a diagnosis, abnormal laboratory findings assessments (e.g., Grade 2 or higher abnormal haematological and biochemical parameters) or other abnormal results the investigator considers clinically significant are recorded as an AE or SAE, if they meet the definition of an AE or SAE.
次要结局
- Frequency of antigen-specific CD8+ T-cells expressing at least two activation markers(At pre-vaccination (Day 1), Day 29, Day 57, Day 85, Day 239 and Day 421)
- Anti-vaccine antibody concentrations(At pre-vaccination (Day 1), Day 29, Day 57, Day 85, Day 239 and Day 421)
- Percentage of seropositive participants for anti-vaccine antibodies(At pre-vaccination (Day 1), Day 29, Day 57, Day 85, Day 239 and Day 421)
- Frequency of antigen specific Cluster of Differentiation (CD)4+ T-cells expressing at least two activation markers(At pre-vaccination (Day 1), Day 29, Day 57, Day 85, Day 239 and Day 421)